LIFETECH SCI (01302) announced that on May 22, 2026, the company intends to acquire approximately 96.46% of the equity in Beijing Huayi Shengjie Technology Co., Ltd. from the seller, AUT-VII HK Holdings Limited. The transaction consideration is approximately 1.8733 billion yuan, which will be settled by the company issuing convertible bonds to the seller. Upon completion of the transaction, Huayi Shengjie will become a non-wholly-owned subsidiary of the company, and its financial performance will be consolidated into the group's financial statements.

Huayi Shengjie is a medical device company primarily engaged in the research and development, manufacturing, and sales of vascular interventional medical devices. Its products are mainly used for treating congenital heart defects and preventing cardiogenic embolic stroke. The company launched one of the first domestically produced congenital heart defect occluders in China in 2003 and introduced the country's first patent foramen ovale (PFO) occluder product in 2009. Huayi Shengjie holds competitive advantages in proprietary technology, market access, and research and development capabilities.

The board of directors believes that the acquisition aligns with the group's overall development strategy and will bring long-term benefits to the company.